12:00 AM
 | 
Mar 11, 2013
 |  BC Week In Review  |  Company News  |  Other News

CoCo Therapeutics neurology news

CoCo Therapeutics debuted earlier this month with undisclosed funding from Advent Venture Partners to develop retinoic acid receptor alpha (RARA) agonists to treat Alzheimer's disease. Founding Chairman Raj Parekh, general partner at Advent, said...

Read the full 159 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >